Launch week offerEnds in00h00m00s

Victoria Leiro

Has grant

Research Scientist

Instituto de Investigação e Inovação em Saúde da Universidade do Porto
Country flagPortugal

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Contracted Researcher

Open Date: 2017-06-01

Close Date:

Grant: Close

Post-doctoral Fellow

Open Date: 2011-04-01

Close Date: 2014-03-01

Grant: Close

Formación de Profesorado Universitario (FPU)

Open Date: 2003-03-01

Close Date: 2007-02-01

Grant: Close

Premio de Licenciatura

Open Date: 2003-01-01

Close Date: 2023-01-01

Grant: Close

Premio Extraordinario de Licenciatura en Química 2002/2003

Open Date: 2003-01-01

Close Date: 2003-01-01

Articles (4)

Year:

2025

Year:

2024

Year:

2023

Alzheimer’s disease (AD) is the most prevalent form of dementia. It affects more than 30 million people worldwide and costs over US$ 1.3 trillion annually. AD is characterized by the brain accumulation of amyloid β peptide in fibrillar structures and the accumulation of hyperphosphorylated tau aggregates in neurons, both leading to toxicity and neuronal death. At present, there are only seven drugs approved for the treatment of AD, of which only two can slow down cognitive decline. Moreover, their use is only recommended for the early stages of AD, meaning that the major portion of AD patients still have no disease-modifying treatment options. Therefore, there is an urgent need to develop efficient therapies for AD. In this context, nanobiomaterials, and dendrimers in particular, offer the possibility of developing multifunctional and multitargeted therapies. Due to their intrinsic characteristics, dendrimers are first-in-class macromolecules for drug delivery. They have a globular, well-defined, and hyperbranched structure, controllable nanosize and multivalency, which allows them to act as efficient and versatile nanocarriers of different therapeutic molecules. In addition, different types of dendrimers display antioxidant, anti-inflammatory, anti-bacterial, anti-viral, anti-prion, and most importantly for the AD field, anti-amyloidogenic properties. Therefore, dendrimers can not only be excellent nanocarriers, but also be used as drugs per se. Here, the outstanding properties of dendrimers and derivatives that make them excellent AD nanotherapeutics are reviewed and critically discussed. The biological properties of several dendritic structures (dendrimers, derivatives, and dendrimer-like polymers) that enable them to be used as drugs for AD treatment will be pointed out and the chemical and structural characteristics behind those properties will be analysed. The reported use of these nanomaterials as nanocarriers in AD preclinical research is also presented. Finally, future perspectives and challenges that need to be overcome to make their use in the clinic a reality are discussed.

Year:

2023

Collaborators (8)

Eran Perlson

Academic, Head, Department Chair Faculty of Medical & Health Science

Tel Aviv University

ISRAEL
View details

M. Cristina Martins

Invited Assistant Professor

Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar

PORTUGAL
View details

Raquel Goncalves

Affiliated Professor

Instituto de Ciências Biomédicas Abel Salazar

PORTUGAL
View details

Ben M. Maoz

Tel Aviv University

ISRAEL
View details

Paula Parreira

Associate Researcher

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto

PORTUGAL
View details

Jose Bessa

Group Leader of the research group "Vertebrate Development and Regeneration"

Instituto de Investigação e Inovação em Saúde da Universidade do Porto

PORTUGAL
View details

Débora Moreira

Junior Investigator

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto

PORTUGAL
View details

Ana P. Pêgo

Principal Investigator

University of Porto

PORTUGAL
View details